Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of “Hold” from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been given an average recommendation of “Hold” by the five brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.00.

A number of analysts recently commented on MIST shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Zacks Research cut shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Finally, Wall Street Zen upgraded shares of Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th.

Milestone Pharmaceuticals Stock Performance

Shares of MIST stock opened at $1.38 on Monday. The company has a current ratio of 8.01, a quick ratio of 7.96 and a debt-to-equity ratio of 1.37. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $3.06. The stock has a market capitalization of $162.38 million, a P/E ratio of -1.75 and a beta of 0.69. The firm’s 50 day moving average is $1.64 and its 200 day moving average is $1.95.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Friday, March 20th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $37.52 million. Research analysts expect that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Insider Buying and Selling at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 43,000 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $2.25, for a total transaction of $96,750.00. Following the completion of the sale, the chief executive officer owned 303,721 shares of the company’s stock, valued at $683,372.25. The trade was a 12.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders have sold 113,693 shares of company stock worth $233,347. Company insiders own 19.50% of the company’s stock.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Propel Bio Management LLC grew its holdings in Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after purchasing an additional 3,333,333 shares during the period. Orbimed Advisors LLC bought a new position in shares of Milestone Pharmaceuticals in the third quarter worth about $6,444,000. Simplify Asset Management Inc. raised its stake in shares of Milestone Pharmaceuticals by 186.2% in the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after buying an additional 1,842,974 shares during the period. Marshall Wace LLP lifted its position in shares of Milestone Pharmaceuticals by 289.8% during the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after buying an additional 1,231,793 shares in the last quarter. Finally, Pathstone Holdings LLC purchased a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at about $2,000,000. 86.18% of the stock is owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.